首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Surgical Outcomes of Patients with Stage IA2 Cervical Cancer Treated with Radical Hysterectomy
【24h】

Surgical Outcomes of Patients with Stage IA2 Cervical Cancer Treated with Radical Hysterectomy

机译:自由基子宫切除术治疗IA2宫颈癌患者的外科疗效

获取原文
           

摘要

Background: This study was undertaken to evaluate the surgical outcomes of patients with stage IA2 cervical cancer treated with radical hysterectomy. Data for 58 patients who underwent modified radical hysterectomy or radical hysterectomy with pelvic lymphadenectomy between January 2003 and December 2012 at Chiang Mai University Hospital were retrospectively reviewed. The analysis included clinico-pathological risk factors (nodal metastasis, parametrial involvement), adjuvant treatment, 5-year disease-free survival and 5-year overall survival. All pathologic slides were reviewed by a gynecologic pathologist. Follow-up methods included at least cervical cytology and colposcopy with directed biopsy if indicated. Univariate analysis was performed to identify factors associated with median survival. At the median follow up time of 73 months, the 5-year disease-free survival and the 5-year overall survival were 97.4% and 97.4%, respectively. Two (3.4%) patients had pelvic lymph node metastases. In a univariate analysis, there was no statistically significant association between survival and prognostic factors such as age, histological cell type, lymph-vascular space invasion, vaginal margin status and lymph node status. Surgical and survival outcomes of women with stage IA2 cervical cancer are excellent. No parametrial involvement was detected in our study. Patients with stage IA2 cervical cancer may be treated with simple or less radical hysterectomy with pelvic lymphadenectomy.
机译:背景:本研究旨在评估用自由基子宫切除术治疗IA2宫颈癌患者的手术结果。回顾性审查了2003年1月至2012年12月在2012年1月至2012年12月期间接受了修饰的自由基子宫切除术或激进子宫切除术的58名患者的数据。分析包括临床病理危险因素(节点转移,参数受累),佐剂治疗,5年无病生存和5年的总体存活。所有病理学幻灯片都被妇科病理学家审查。随访方法包括至少具有指向活组织检查的宫颈细胞学和阴道镜检查。进行单变量分析以确定与中位生存期相关的因素。在73个月的中位后续时间,5年的疾病生存和5年的整体生存率分别为97.4%和97.4%。两种(3.4%)患者患有盆腔淋巴结转移。在单变量分析中,存活率和预后因素之间没有统计学上显着的关联,如年龄,组织学细胞类型,淋巴结空间侵袭,阴道边缘状态和淋巴结状态。 IA2宫颈癌患者的外科和生存结果是优秀的。在我们的研究中没有检测到参数参数。患有术阶段宫颈癌的患者可以用简单或更少的自由基子宫切除术治疗骨盆淋巴结切除术治疗。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号